US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney ...

Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Biogen has announced that it has initiated a late-stage study of felzartamab in adult kidney transplant recipients who have been diagnosed with late antibody-mediated rejection (AMR). The phase 3 ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...